For the roughly 5–10% of kidney transplant candidates who accumulate such broad HLA antibody profiles that compatible donor organs almost never become available, dialysis can stretch into decades — a sentence that dramatically shortens lifespan and diminishes quality of life. A German expert consensus from the Kidney and Immunology Commissions of the German Transplantation Society now proposes a structured clinical pathway to break that deadlock, combining strategic HLA antigen delisting with perioperative use of the IgG-cleaving enzyme imlifidase.
The framework addresses a population that sits in a gap left by existing programs: candidates either ineligible for or inadequately served by Eurotransplant's Acceptable Mismatch (AM) program. Rather than waiting indefinitely, the protocol proposes risk-adapted "delisting" of specific unacceptable HLA antigens — selectively removing some antibody specificities from a candidate's incompatibility list — in carefully selected individuals. Imlifidase, a streptococcal cysteine protease that cleaves all four IgG subclasses within hours, is positioned as a perioperative desensitization bridge, enabling transplantation across otherwise prohibitive HLA barriers. The consensus covers candidate selection criteria, multidisciplinary governance, organ offer assessment, perioperative immunosuppression regimens, infection prophylaxis, and protocols for monitoring and treating antibody-mediated rejection post-transplant.
This consensus reflects a meaningful clinical evolution rather than a paradigm shift — the science of imlifidase has been building since its European Medicines Agency approval in 2021, and HLA delisting strategies have existed conceptually for years. What this document adds is a unified governance framework for deploying both tools together, specifically calibrated to Germany's legal requirement to balance transplant urgency against likelihood of success. The key limitation is that consensus documents, however expert-driven, are not randomized evidence; outcomes data for imlifidase-enabled transplantation remain limited to registries and small cohorts, with long-term rejection rates still incompletely characterized. For experienced transplant centers globally, this framework offers a reproducible template, though adaptation to local allocation law and immunological infrastructure will be essential.